Skip to main navigation

Main navigation

  • About
    • Who We Are
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Therapeutic Areas
    • Gorlin Syndrome
    • Pachyonychia Congenita
    • Acne Vulgaris
    • Inflammatory Lesions of Rosacea
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Analyst Coverage
    • Financial Information
    • Stock Information
    • Shareholder Services
  • Media
  • Contact

Press Releases

Date Title  
May 13, 2021
Summary ToggleSol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
 
Apr 27, 2021
Summary ToggleSol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
 
Mar 04, 2021
Summary ToggleSol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
 
Feb 24, 2021
Summary ToggleSol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
 
Jan 11, 2021
Summary ToggleSol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
 
Dec 07, 2020
Summary ToggleSol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
 
Nov 12, 2020
Summary ToggleSol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
 
Nov 09, 2020
Summary ToggleSol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
 
Nov 04, 2020
Summary ToggleSol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
 
Sep 10, 2020
Summary ToggleSol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea
 

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last
Displaying 31 - 40 of 97 results

Investor Relations

  • Investor Overview
  • Press Releases
  • Events & Presentations
    • Events
  • Corporate Governance
    • Documents and Charters
    • Committee Composition
  • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Proxy Statement
  • Stock Information
    • Stock Quote & Chart
  • Shareholder Services
    • FAQs
    • Contact
    • Email Alerts

Shareholder Tools

Print
Print
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds

Who We Are

We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

What We Do

Footer What We Do

  • About
  • Technology
  • Pipeline

Get In Touch

Footer Get In Touch

  • Contact Us
  • Partnering

Subscribe!

Subscribe to receive updates
Sign-up

© 2023 Sol-Gel Technologies Ltd. All Rights Reserved